DEFA14A: Alnylam Pharmaceuticals Sets Date for 2025 Annual Meeting, Outlines Key Proposals for Shareholder Vote

Alnylam Pharmaceuticals announces its 2025 Annual Meeting of Stockholders, urging shareholders to vote on key proposals including the election of directors, approval of an amendment to the Restated Certificate of Incorporation, approval of the second amended and restated 2018 Stock Incentive Plan, an advisory vote on executive compensation, and ratification of the appointment of PricewaterhouseCoopers LLP as independent auditors.

Summary

• Alnylam Pharmaceuticals has scheduled its Annual Meeting of Stockholders for May 8, 2025.
• Shareholders are encouraged to vote on several key proposals.
• The proposals include the election of four Class III directors: Carolyn R. Bertozzi, Margaret A. Hamburg, Colleen F. Reitan, and Amy W. Schulman.
• Another proposal seeks to approve an amendment to the Restated Certificate of Incorporation allowing for officer exculpation.
• Shareholders will also vote on the second amended and restated 2018 Stock Incentive Plan.
• An advisory, non-binding vote will be held on the compensation of Alnylam's named executive officers.
• The final proposal involves ratifying the appointment of PricewaterhouseCoopers LLP as the company's independent auditors for the fiscal year ending December 31, 2025.
• Shareholders can access proxy materials and vote online at www.ProxyVote.com.
• The deadline to vote shares held in a 401(k) Plan is May 5, 2025, at 11:59 PM ET, while the general voting deadline is May 7, 2025, at 11:59 PM ET.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral to slightly positive sentiment as it reflects the company's adherence to corporate governance practices.

Positives

• The company is providing shareholders with multiple avenues to access proxy materials and vote, including online, phone, and email.
• The proposals presented appear to be standard corporate governance matters.

Future Outlook

The document outlines the business to be conducted at the upcoming annual meeting.

Industry Context

This is a standard proxy statement related to an annual shareholder meeting, a routine event for publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders are directly impacted by the proposals being voted on.
• Employees may be affected by the approval of the stock incentive plan.
• The outcome of the vote on officer exculpation could impact the risk profile for company directors and officers.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals by the specified deadlines.
• The company will hold its Annual Meeting of Stockholders on May 8, 2025.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Officer Exculpation, Stock Incentive Plan, Executive Compensation, Auditors, PricewaterhouseCoopers, Alnylam Pharmaceuticals